Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,245 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Assessment and Follow Up Evaluation Clear all
Completed Phase 2 Interventional

Conversational IT for Better, Safer Pediatric Primary Care

NCT01188629
View directory record Official record
Conditions
Preventive Care, Medication Management
Interventions
Safety Training, Personal Health Partner and Counseling (PHP+C)
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
Up to 11 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)

NCT02623699
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Tofersen, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
20
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

NCT01494987
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Glimepiride, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 10, 2026, 2:12 PM EDT
Recruiting No phase listed Observational

A Long Term Follow-up Study of TScan TCR-T Products

NCT06976736
View directory record Official record
Conditions
AML, ALL, MDS
Interventions
Observational
Other
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

NCT03251092
View directory record Official record
Conditions
Healthy Volunteer - Complete, Cystic Fibrosis - Complete
Interventions
PTI-808, Placebo, PTI-428, PTI-801
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
22
States / cities
Tucson, Arizona • Stanford, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

NCT05188729
View directory record Official record
Conditions
Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin, Carcinoma
Interventions
Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose, Part 2: VP-315 2 Day Dosing/Week - Split Dose, Part 2: VP-315 3 Day Dosing/Week - Split Dose
Drug
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
San Diego, California • Boca Raton, Florida • Coral Springs, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects

NCT04838639
View directory record Official record
Conditions
Obesity
Interventions
NO-13065, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 10, 2026, 2:12 PM EDT
Completed No phase listed Observational Results available

Safety and Performance of MICRORAPTOR™ Suture Anchors in Shoulder and Hip

NCT03985839
View directory record Official record
Conditions
Labral Tear, Glenoid, Acetabular Labrum Tear, Bankart Lesions, Anterior Shoulder Instability, SLAP Lesion, Rotator Cuff Tears
Interventions
MICRORAPTOR™ REGENESORB™ Suture Anchor, MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor, MICRORAPTOR™ Knotless PEEK Suture Anchor
Device
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
12 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Oakland Park, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

NCT05063539
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3372689, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
35
States / cities
Canoga Park, California • Fresno, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

NCT03276728
View directory record Official record
Conditions
Heart Failure, Healthy Volunteer
Interventions
AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
8
States / cities
Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional

Treatment of Erectile Dysfunction - Long Term Safety and Efficacy

NCT01065012
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Udenafil 50 mg, Udenafil 100 mg, Udenafil 150 mg, Placebo Matching 50 mg Udenafil, Placebo Matching 100 mg Udenafil, Placebo Matching 150 mg Udenafil
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
19 Years and older · Male only
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
72
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 65 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 10, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

Development and Feasibility of CTraC-FIT

NCT07132944
View directory record Official record
Conditions
Functional Impairment, Functional Performance
Interventions
CTraC-FIT, Enhanced Usual Care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

NCT05139121
View directory record Official record
Conditions
Contraception
Interventions
MR-100A-01
Drug
Lead sponsor
Mylan Technologies Inc.
Industry
Eligibility
16 Years and older · Female only
Enrollment
1,320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
96
States / cities
Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder

NCT02431806
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Levomilnacipran, Fluoxetine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
12 Years to 17 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
48
States / cities
Dothan, Alabama • Tucson, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 10, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional Results available

Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma

NCT00006478
View directory record Official record
Conditions
Lymphoma
Interventions
autologous tumor cell vaccine, keyhole limpet hemocyanin, sargramostim, adjuvant therapy
Biological · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 10, 2026, 2:12 PM EDT
Terminated No phase listed Observational

Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T

NCT04201782
View directory record Official record
Conditions
HIV-1-infection
Interventions
There are no disallowed treatments
Drug
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
4
States / cities
San Francisco, California • Norwalk, Connecticut • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Oct 10, 2026, 2:12 PM EDT
Enrolling by invitation No phase listed Observational

Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

NCT07503613
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Not listed
Lead sponsor
Akouos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Ambulatory Alcohol Detoxification With Remote Monitoring

NCT03582150
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Remote Monitoring with Ambulatory Detox
Device
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 10, 2026, 2:12 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

NCT07811297
View directory record Official record
Conditions
Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
Interventions
AL58805, AL3818, Temozolomide (TMZ), CCNU
Drug
Lead sponsor
Advenchen Pharmaceuticals, LLC.
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)

NCT07429240
View directory record Official record
Conditions
Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
Interventions
PBGENE-DMD (IV)
Biological
Lead sponsor
Precision BioSciences, Inc.
Industry
Eligibility
2 Years to 7 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Little Rock, Arkansas • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

NCT00761150
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
ABT-712, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
21 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
32
States / cities
Tempe, Arizona • Tucson, Arizona • Anaheim, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 10, 2026, 2:12 PM EDT
Terminated Not applicable Interventional Results available

Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

NCT00870818
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
Diagnostic Test · Behavioral
Lead sponsor
MacroGenics
Industry
Eligibility
10 Years to 37 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 10, 2026, 2:12 PM EDT
Not yet recruiting Not applicable Interventional

First Responder Safety Training (FiRST)

NCT07478250
View directory record Official record
Conditions
Resilience and Mental Health of First Responders
Interventions
Worker Resilience Training Program, Fire and Medical Safety (FAMS)
Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Stony Brook, New York • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04182204
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Polatuzumab Vedotin, Rituximab, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Jacksonville, Florida • Pembroke Pines, Florida • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 10, 2026, 2:12 PM EDT